Core Insights - Dentsply International reported $904 million in revenue for Q3 2025, a year-over-year decline of 4.9%, with an EPS of $0.37 compared to $0.50 a year ago, indicating a significant drop in earnings [1] - The revenue exceeded the Zacks Consensus Estimate of $901.59 million by 0.27%, while the EPS fell short of the consensus estimate of $0.45 by 17.78% [1] Revenue Breakdown - Revenue in the United States was $291 million, below the estimated $333.9 million, reflecting a year-over-year decline of 22.2% [4] - Revenue from the Rest of the World reached $231 million, slightly above the estimated $211.1 million, marking a year-over-year increase of 0.4% [4] - European revenue was $382 million, surpassing the average estimate of $360.92 million, with a year-over-year growth of 10.1% [4] Net Sales Performance - Connected Technology Solutions reported net sales of $259 million, slightly above the estimate of $253.17 million, but down 3.7% year over year [4] - Wellspect Healthcare achieved net sales of $83 million, exceeding the estimate of $76.63 million, with a year-over-year increase of 15.3% [4] - Essential Dental Solutions had net sales of $357 million, below the estimate of $367.93 million, reflecting a year-over-year decline of 3.3% [4] - Orthodontic and Implant Solutions reported net sales of $205 million, slightly above the estimate of $202.59 million, with a year-over-year decrease of 14.9% [4] Adjusted Operating Income - Adjusted Operating Income for Connected Technology Solutions was $10 million, significantly below the estimate of $19.2 million [4] - Wellspect Healthcare's Adjusted Operating Income was $28 million, above the average estimate of $24 million [4] - Orthodontic and Implant Solutions reported Adjusted Operating Income of $22 million, exceeding the estimate of $15.66 million [4] - Essential Dental Solutions had Adjusted Operating Income of $116 million, below the estimate of $127.61 million [4] Stock Performance - Dentsply's shares returned +1.9% over the past month, outperforming the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - DENTSPLY SIRONA is undergoing a significant transformation under new CEO Daniel T. Scavilla, focusing on a return to growth through a comprehensive action plan aimed at improving customer experience, operational efficiency, and financial performance. Financial Performance - For Q3 2025, global sales were $940 million, a decrease of 5% as reported and 8% on a constant currency basis, with adjusted EBITDA at 18.4%, up 50 basis points from the prior year [8][10] - Non-GAAP earnings per share for the prior year was $0.37, down $0.13, attributed to sales mix impacts and higher tax rates [9] - Cash from operations was $79 million, with an ending cash balance of $363 million [10] - The company recorded a $263 million non-cash after-tax charge related to goodwill and intangible asset impairment [10] Regional Sales Performance - US sales were $291 million, down 22.2% year-over-year, while European sales increased by 9.9% [12][13] - Sales in the Rest of World segment were $231 million, showing slight declines, with notable growth in Australia and India [13] Strategic Initiatives - The return to growth action plan consists of four key pillars: putting customers at the center, reigniting the US business, empowering people, and evolving operations [17] - The company aims to enhance customer experience by creating a global customer service organization and improving support for field-based employees [20][21] - A comprehensive plan is in place to strengthen the US commercial foundation, including aligning teams and enhancing decision-making processes [21][22] Leadership Changes - Matthew E. Garth, the former CFO, has departed the company, and a transition plan is in place to ensure continuity [6][7] - The company is actively searching for a new CFO who can leverage data for strategic decision-making [70] Future Outlook - The revised outlook for 2025 includes net sales in the range of $3.6 billion to $3.7 billion, with constant currency sales expected to decline by 5% to 4% year-over-year [16] - The company plans to increase investments in R&D and clinical education to support growth initiatives [47][74] Market Positioning - DENTSPLY SIRONA is focusing on strengthening its relationships with dealers and enhancing its direct sales approach, particularly in the implant market [58][81] - The company recognizes the need for improved training and presence in the market to better serve dental professionals [81]

Financial Data and Key Metrics Changes - For Q3 2025, global sales were $904 million, a decrease of 5% as reported, or negative 8% on a constant currency basis [7] - Adjusted EBITDA was 18.4%, up 50 basis points versus the prior year, driven by lower sales on favorable product and geography mix [8] - Non-GAAP earnings per share was $0.37, down $0.13 versus the prior year, with approximately half of the decline reflecting impacts of sales mix and tariffs [9] Business Line Data and Key Metrics Changes - Sales in the U.S. were $291 million, down 22.2% year-over-year, driven by lower sales in Essential Dental Solutions, CAD/CAM, Imaging, and Implants [10] - European sales were $382 million, increasing 9.9% as reported, or 2.6% on a constant currency basis, driven by growth in Connected Technology Solutions and labs [10] - Wellspect Healthcare sales grew 9.3% in Europe on a constant currency basis, with significant growth in the Rest of World segment [12] Market Data and Key Metrics Changes - U.S. sales were down 22.2%, while European sales increased 9.9%, indicating a divergence in market performance [10] - The Rest of World sales were $231 million, down slightly versus the prior year, with strength in Essential Dental Solutions offset by declines in Connected Technology Solutions and implants [11] Company Strategy and Development Direction - The company is focusing on a return-to-growth action plan with four key pillars: putting customers at the center, reigniting the U.S. business, empowering people, and evolving operations [14] - A transition plan is in place following the departure of the CFO to ensure continuity and maintain financial discipline [6][20] - The company plans to increase investments in R&D to improve product development processes and enhance customer experience [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need for bold changes and emphasized a commitment to reposition the company as a market leader [27] - The revised outlook for 2025 includes net sales in the range of $3.6 billion to $3.7 billion, with constant currency sales expected to decline by 5% to 4% year-over-year [13] - Management expressed confidence in the company's potential and the importance of executing the return-to-growth plan [26] Other Important Information - The company recorded a $263 million non-cash after-tax charge related to the impairment of goodwill and intangible assets due to tariffs and lower projected volumes [9] - The Wellspect Healthcare business will play a key role in achieving financial goals, with a decision made to retain the business for greater strategic benefit [25] Q&A Session Summary Question: Insights on the U.S. market performance - Management indicated that the U.S. market's decline is due to multiple factors, including structural approach and execution issues [31][32] Question: Cadence of growth over the next two years - Management stated that while they desire to return to growth quickly, they need more time to refine the growth plan and establish a timeline for improvements [35][36] Question: Capital allocation philosophy and dividend importance - Management emphasized the need to explore the value of dividends and prioritize business growth and debt retirement [37][38] Question: R&D investment acceleration - Management confirmed plans to pull forward R&D investments to strengthen the company's position for 2026 and beyond [40][42] Question: Characteristics sought in a new CFO - Management is looking for a CFO who can analyze data effectively and communicate meaningful metrics to drive the company's return-to-health strategy [64][65]

Financial Performance - Dentsply Sirona reported a net loss of $428 million for the three months ended September 30, 2025, compared to a net loss of $495 million for the same period in 2024, reflecting a 13.5% improvement year-over-year[13]. - Total comprehensive loss for the nine months ended September 30, 2025, was $394 million, a decrease from $482 million in the same period of 2024, indicating an 18.3% reduction in losses[13]. - Net loss for the nine months ended September 30, 2025, was $453 million, compared to a loss of $482 million for the same period in 2024[19]. - The total comprehensive loss for the three months ended September 30, 2025, was $459 million, slightly higher than the $456 million reported in the same period of 2024[13]. - Comprehensive loss attributable to Dentsply Sirona was $458 million for the three months ended September 30, 2025, compared to $455 million in the prior year[13]. - For the nine months ended September 30, 2025, the net loss was $453 million, an improvement from a net loss of $482 million in the same period of 2024[13]. - The total comprehensive loss for the nine months ended September 30, 2025, was $395 million, compared to $484 million in the same period of 2024[13]. - The company continues to focus on improving its financial performance despite ongoing losses in both net and comprehensive categories[13]. Cash and Liquidity - Cash and cash equivalents increased to $363 million as of September 30, 2025, up from $272 million at the end of 2024, representing a 33.5% increase[15]. - Cash provided by operating activities for the nine months ended September 30, 2025, was $134 million, down from $374 million in 2024[19]. - The company reported a net increase in cash and cash equivalents of $91 million for the nine months ended September 30, 2025[19]. - Total cash and cash equivalents at the end of the period was $363 million, compared to $296 million at the end of September 2024[19]. - The company had $736 million available under lines of credit as of September 30, 2025[190]. Sales and Revenue - Total net sales for the three months ended September 30, 2025, were $904 million, a decrease of 4.9% compared to $951 million in the same period of 2024[29]. - For the nine months ended September 30, 2025, total net sales were $2,719 million, down 5.9% from $2,888 million in 2024[29]. - The Orthodontic and Implant Solutions segment saw a significant decline, with net sales dropping by $36 million (15.0%) to $205 million for the three months ended September 30, 2025, primarily due to lower volumes of clear aligners following the suspension of Byte sales[143][145]. - The United States region experienced a notable decline in net sales, down $83 million (22.2%) to $291 million for the three months ended September 30, 2025, primarily due to lower volumes of Byte products and CAD/CAM equipment[147][148]. - The Essential Dental Solutions segment saw a decrease in net sales by $12 million (3.4%) to $357 million for the three months ended September 30, 2025, mainly due to lower sales of preventive and restorative products[141][142]. - Net sales in Europe increased by $35 million (9.9%) to $382 million for the three months ended September 30, 2025, primarily due to higher volumes of treatment centers and imaging equipment[150][151]. Expenses and Costs - SG&A expenses decreased by $35 million (8.8%) to $355 million for the three months ended September 30, 2025, and by $149 million (12.3%) to $1,055 million for the nine months ended September 30, 2025, primarily due to lower marketing expenses and headcount costs[158]. - R&D expenses decreased by $3 million (9.2%) to $37 million for the three months ended September 30, 2025, and by $13 million (10.9%) to $110 million for the nine months ended September 30, 2025, as the company continues to prioritize investments in digital workflow solutions and product development[160]. - The company incurred restructuring and other costs of $18 million for the nine months ended September 30, 2025, compared to $45 million in the same period of 2024, a decrease of 60%[50]. - Restructuring costs decreased to $5 million for the three months ended September 30, 2025, from $23 million in the same period of 2024, and to $18 million for the nine months ended September 30, 2025, from $45 million in 2024[163]. Assets and Liabilities - Total assets decreased to $5,653 million as of September 30, 2025, down from $5,753 million at December 31, 2024, a decline of 1.7%[15]. - Long-term debt increased to $2,017 million from $1,586 million, representing a 27.2% increase[15]. - The accumulated deficit grew to $1,385 million as of September 30, 2025, compared to $835 million at the end of 2024, indicating a 65.8% increase[15]. - Dentsply Sirona's total equity decreased to $1,478 million from $1,943 million, a decline of 23.8%[15]. - The company's total net debt to total capitalization ratio increased to 57.9% as of September 30, 2025, compared to 48.9% at December 31, 2024[190]. Impairments and Charges - Goodwill asset impairment for the nine months ended September 30, 2025, was $409 million, compared to $504 million in 2024[19]. - The Company recorded pre-tax goodwill impairment charges of $262 million for the three months ended September 30, 2025, and $409 million for the nine months ended September 30, 2025, primarily related to the Implant & Prosthetic Solutions reporting unit[161][162]. - An additional pre-tax goodwill impairment charge of $253 million was recorded for the same reporting unit as of September 30, 2025, driven by lower-than-expected volumes[87]. Legal and Regulatory Matters - The Company is involved in multiple securities litigations, including a consolidated class action in the SDNY Court, with claims alleging violations of U.S. securities laws from June 9, 2021, to May 9, 2022[92]. - The Company continues to incur significant legal fees related to these pending cases and may face substantial damages if any lawsuits are decided adversely[107][108]. - The IRS is examining the Company's U.S. federal income tax returns for 2015 and 2016, proposing an adjustment that could result in additional federal income taxes on a distribution of $451 million related to a stock redemption[109]. - The SEC concluded its investigation of the Company and does not intend to recommend any enforcement action against it as of October 14, 2025[93]. Market Conditions and Challenges - The Company has experienced higher prices for certain raw materials, negatively impacting margins, and is facing challenges due to macroeconomic conditions affecting consumer confidence and discretionary spending[124][125]. - The Company delivered a one-year notice of non-renewal for its distribution agreements with Patterson Companies, which could materially affect its business if new agreements are not secured[132]. - The Company's operations in Israel, which contributed approximately 3% of consolidated net sales, remain unaffected by geopolitical conflicts, although sales to Turkey have been impacted by import restrictions[129][130].

Core Insights - Dentsply International reported quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share, and down from $0.50 per share a year ago, representing an earnings surprise of -17.78% [1] - The company posted revenues of $904 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.27%, but down from $951 million year-over-year [2] - Dentsply shares have declined approximately 33.5% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.47 on revenues of $931.32 million, and for the current fiscal year, it is $1.87 on revenues of $3.65 billion [7] Estimate Revisions - The trend of estimate revisions for Dentsply was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Performance - Net sales decreased by 50% year-over-year, reaching $904 million in Q3 2025 compared to $951 million in Q3 2024[9] - Constant currency net sales decreased by 80%, including a 55% impact from Q3 2024 Byte impact and ERP pre-buy[14, 16] - Adjusted EBITDA margin increased by 50 bps year-over-year to 184%[9, 11, 16] - Adjusted EPS decreased by 265% year-over-year to $037[9, 12, 16] - Operating cash flow was $79 million[9, 13] Segment Results - Connected Technology Solutions (CTS) sales decreased by 39% as reported and 70% in constant currency[17] - Essential Dental Solutions (EDS) sales decreased by 34% as reported and 62% in constant currency, primarily due to a $24 million Q3 2024 pre-buy[17] - Orthodontic and Implant Solutions (OIS) sales decreased by 150% as reported and 171% in constant currency, impacted by a ~$30 million Byte year-over-year impact[17] - Wellspect Healthcare sales increased by 156% as reported and 93% in constant currency[17] Geographic Performance - U S net sales decreased by 222% in constant currency, including a 125% impact from Q3 2024 Byte impact and ERP pre-buy, reaching $291 million[16] - Europe net sales increased by 26% in constant currency, reaching $382 million[16] - Rest of World net sales decreased by 09% in constant currency, reaching $231 million[16] Revised Outlook - The company revised its 2025 constant currency outlook to a decline of 5% to 4%[19] - The company maintains its reported sales outlook at $36 billion - $37 billion[19] - The company revised its adjusted EBITDA margin outlook to >18%[19] - The company revised its adjusted EPS outlook to ~$160[19]

Dentsply Sirona Reports Third Quarter 2025Results Charlotte, N.C., November 6, 2025 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2025 and introduced its Return-to-Growth action plan, a comprehensive strategy to improve performance and position the Company for sustained, profitable growth over the next 24 months. Third quarter net sales of $904 million decreased (5.0%) (decreased (8.0%) in constant currency) compared ...

Core Insights - Dentsply Sirona reported a net sales decrease of 5.0% to $904 million in Q3 2025, with a net loss of $427 million, an improvement from a loss of $494 million in Q3 2024 [2][3][7] - The company introduced a Return-to-Growth action plan aimed at improving performance and achieving sustained, profitable growth over the next 24 months [3][4] Financial Performance - Q3 2025 net sales of $904 million decreased by 5.0% year-over-year, with a constant currency decrease of 8.0% [2][9] - Adjusted earnings per diluted share were $0.37, down from $0.50 in Q3 2024, while adjusted EBITDA margin improved to 18.4% from 17.9% [2][11][45] - The company recorded a non-cash goodwill impairment charge of $263 million in Q3 2025, compared to $504 million in Q3 2024 [15][41] Return-to-Growth Action Plan - The action plan focuses on four key pillars: enhancing customer experience, reigniting U.S. business growth, empowering employees, and evolving operations for innovation [4][10] - Leadership changes have been made to support the action plan, including the appointment of a new Chief Commercial Officer and a Chief Transformation Officer [5][10] Revised Outlook - Dentsply Sirona revised its 2025 outlook, projecting net sales between $3.6 billion and $3.7 billion, with adjusted EPS expected to be approximately $1.60 [5][6] - The company anticipates a year-over-year sales decline of 5% to 4% in constant currency for 2025 [5] Segment and Geographic Performance - In Q3 2025, the Orthodontic and Implant Solutions segment saw a significant sales decline of 15.0%, while Wellspect Healthcare experienced a growth of 15.6% [12][13] - Geographic performance showed a 22.2% decline in the U.S., contrasted with a 9.9% increase in Europe [13][39] Cash Flow and Liquidity - Operating cash flow for Q3 2025 was $79 million, down from $141 million in Q3 2024, primarily due to unfavorable working capital changes [14] - The company had $363 million in cash and cash equivalents as of September 30, 2025 [14][21]

Core Insights - DENTSPLY SIRONA Inc. is set to report its third-quarter 2025 results on November 6, with expectations of mixed performance due to various market pressures [2][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $901.6 million, while earnings are expected to be 45 cents per share. The company's own estimates are slightly higher for revenues at $904 million but lower for earnings at 42 cents per share [3]. - In the previous quarter, the company reported a 4.9% year-over-year decline in sales to $936 million, primarily due to weaknesses in Orthodontic & Implant Solutions and Connected Technology Solutions [5]. Market Conditions - The company is facing tariff-related cost pressures, subdued U.S. demand, and ongoing product transitions, which are expected to impact both revenues and margins in the upcoming quarter [4][6]. - Management has maintained its full-year outlook, indicating confidence in its cost structure despite the challenges [6]. Segment Analysis - **Essential Dental Solutions (EDS)**: Expected to show modest low-single-digit growth, with revenues estimated to decline 0.5% organically to $370.5 million, supported by stable patient traffic globally [7]. - **Orthodontic & Implant Solutions (OIS)**: Anticipated to be a significant drag, with a projected 19.7% organic revenue decline to $195.2 million, impacted by the phase-out of the Byte aligner business and weak implant demand [8][10]. - **Connected Technology Solutions (CTS)**: Expected to face continued weakness, with revenues estimated to decline 2.8% organically to $264.4 million, as U.S. dental offices reduce capital equipment purchases [11]. - **Wellspect Healthcare**: Projected to stabilize with a 0.9% organic revenue increase to $73.9 million, supported by new product introductions [12]. Earnings Prediction - The current model does not predict an earnings beat for DENTSPLY SIRONA, with an Earnings ESP of -2.46% and a Zacks Rank of 3 (Hold) [13][14].